Unknown

Dataset Information

0

Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4.

ABSTRACT: Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), L1Mab-4 (IgG2b, kappa), using cell-based immunization and screening (CBIS) method and investigated hPD-L1 expression in oral cancers. L1Mab-4 reacted with oral cancer cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-3, and HSC-4) in flow cytometry and stained oral cancers in a membrane-staining pattern. L1Mab-4 stained 106/150 (70.7%) of oral squamous cell carcinomas, indicating the very high sensitivity of L1Mab-4. These results indicate that L1Mab-4 could be useful for investigating the function of hPD-L1 in oral cancers.

SUBMITTER: Yamada S 

PROVIDER: S-EPMC5857169 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L<sub>1</sub>Mab-4.

Yamada Shinji S   Itai Shunsuke S   Kaneko Mika K MK   Kato Yukinari Y  

Biochemistry and biophysics reports 20180206

Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), L<sub>1</sub>Mab-4 (IgG<sub>2b</sub>, kappa), using c  ...[more]

Similar Datasets

Unknown Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5.
| S-EPMC5986985 | biostudies-literature
Unknown PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
| S-EPMC7881100 | biostudies-literature
Unknown Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.
| S-EPMC5777972 | biostudies-literature
Unknown Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
| S-EPMC4898770 | biostudies-literature
Unknown CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
| S-EPMC6804456 | biostudies-literature
Unknown A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
| S-EPMC5567082 | biostudies-literature
Unknown PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.
| S-EPMC4589506 | biostudies-literature
Unknown Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
| S-EPMC5925824 | biostudies-literature
Unknown Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.
| S-EPMC6279860 | biostudies-literature
Unknown Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
| S-EPMC6360219 | biostudies-literature